{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:33:50Z","timestamp":1787924030046,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacasi.2026.03.031","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:35:27Z","timestamp":1779334527000},"page":"1517-1527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-2519","authenticated-orcid":false,"given":"Jin","family":"Endo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-259X","authenticated-orcid":false,"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Onoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongshu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chan-Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-0904","authenticated-orcid":false,"given":"Darae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2026.03.031_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jacasi.2026.03.031_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacasi.2026.03.031_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2026.03.031_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"Nativi-Nicolau","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacasi.2026.03.031_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob Heart"},{"key":"10.1016\/j.jacasi.2026.03.031_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.03.031_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","article-title":"Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review","volume":"20","author":"Delgado","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacasi.2026.03.031_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","article-title":"Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan","volume":"8","author":"Winburn","year":"2019","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jacasi.2026.03.031_bib9","article-title":"Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacasi.2026.03.031_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/13506129.2023.2180334","article-title":"Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis","volume":"30","author":"Naiki","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jacasi.2026.03.031_bib11","article-title":"Diagnostic pitfall and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study","volume":"39","author":"Kim","year":"2024","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jacasi.2026.03.031_bib12","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/ehf2.14364","article-title":"Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan","volume":"10","author":"Naito","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.03.031_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/13506129.2024.2426508","article-title":"High frequency of occult transthyretin and apolipoprotein AI-type amyloid in aortic valves removed by valve replacement for aortic stenosis","volume":"32","author":"Honda","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.jacasi.2026.03.031_bib14","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.03.031_bib15","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.03.031_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13023-022-02425-3","article-title":"Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis","volume":"17","author":"Jang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacasi.2026.03.031_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1253\/circrep.CR-25-0031","article-title":"Real-world clinical impact of tafamidis on transthyretin amyloid cardiomyopathy\u2014a decade of experience from a community-based hospital (2015-2024)","volume":"7","author":"Kubota","year":"2025","journal-title":"Circ Rep"},{"key":"10.1016\/j.jacasi.2026.03.031_bib18","author":"Yun-Mi"},{"key":"10.1016\/j.jacasi.2026.03.031_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.03.031_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacasi.2026.03.031_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jacasi.2026.03.031_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.03.031_bib23","series-title":"AMVUTTRA (vutrisiran sodium)\u2014Japanese prescribing information","year":"2022"},{"key":"10.1016\/j.jacasi.2026.03.031_bib24","series-title":"Drug Approval Report","year":"2024"},{"key":"10.1016\/j.jacasi.2026.03.031_bib25","series-title":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","author":"Jain","year":"2025"},{"key":"10.1016\/j.jacasi.2026.03.031_bib26","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.03.031_bib27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/clc.23882","article-title":"Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia","volume":"45","author":"Lin","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacasi.2026.03.031_bib28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1253\/circj.CJ-23-0453","article-title":"A reliable baton passing from orthopedic surgeon to cardiologist\u2014cardiac screening in patients with carpal tunnel syndrome for early diagnosis of transthyretin amyloid cardiomyopathy","volume":"87","author":"Ikura","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2026.03.031_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1253\/circj.CJ-23-0948","article-title":"Efficacy of computed tomography-based evaluation of myocardial extracellular volume combined with red flags for early screening of concealed cardiac amyloidosis in patients with atrial fibrillation","volume":"88","author":"Yamasaki","year":"2024","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2026.03.031_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1253\/circj.CJ-24-0479","article-title":"Prospective multicenter screening with high-sensitivity cardiac troponin T for wild-type transthyretin cardiac amyloidosis in outpatient and community-based settings","volume":"89","author":"Arima","year":"2024","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2026.03.031_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:09:32Z","timestamp":1787922572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374726001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2772374726001924"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.03.031","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}